41680-09-5

Basic information

• Product Name: Liquiritigenin
• Synonyms: (?à)-4',7-Dihydroxyflavanone; (?à)-Liquiritigenin
• CAS NO: 41680-09-5
• Molecular Formula: C15H12O4
• Molecular Weight: 0
• Mol File: 41680-09-5.mol
• Article Data: 32

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Liquiritigenin(CAS DataBase Reference)
• NIST Chemistry Reference: Liquiritigenin(41680-09-5)
• EPA Substance Registry System: Liquiritigenin(41680-09-5)

Safety Data

• Hazardous Substances Data: 41680-09-5(Hazardous Substances Data)

Usage

General Description

Liquiritigenin is a flavonoid compound that is found in various plants, with licorice root being a particularly rich source. It has been studied for its potential therapeutic properties, including anti-inflammatory, antioxidant, and anti-cancer effects. Liquiritigenin has shown promise in inhibiting the growth and spread of cancer cells in laboratory studies, as well as reducing inflammation and oxidative stress in animal models. Additionally, it may have potential as a treatment for diseases such as diabetes and cardiovascular disorders. Research into the pharmacological properties of liquiritigenin is ongoing, and it has garnered interest for its potential as a natural remedy for various health conditions.

Upstream product

• 551-15-5 liquiritin(sh) 
• 961-29-5 isoliquirtigenin 
• 25826-69-1 4',7-dimethoxyflavanone 
• 78316-24-2 7,4'-di(methoxymethoxy)flavan-4-one 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 13745-20-5 2',4,4'-trihydroxychalcone 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 2196-14-7 7,4'-Dihydroxyflavon 
• 1085453-61-7 ethyl 4-(triisopropylsilyloxy)benzoate 
• 23423-35-0 (E)‐3‐(4‐hydroxyphenyl)‐1‐(2,4‐dimethoxyphenyl)prop‐2‐en‐1‐one 
• 133346-24-4 1-(2,4-dihydroxyphenyl)-3-hydroxy-3-(4'-hydroxyphenyl)-1-propanone 
• 69097-97-8 7,4'-dihydroxy-dihydroflavone 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 101097-68-1 liquiritigenin oxime 
• 131887-80-4 (2R,3S)-2,7,4'-trihydroxyisoflavanone 
• 578-86-9 liquiritigenin 
• 31524-62-6 ((2S)-2,3-dihydro-7-hydroxy-2-hydroxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one 
• 59870-65-4 Glabrol 
• 59870-65-4 glabrol 
• 101097-68-1 liquiritigenin oxime 
• 59121-64-1 liquiritigenin 7,4′-diacetate 

Relevant articles and documents

Liquiritigenin inhibits hepatic fibrogenesis and TGF-β1/Smad with Hippo/YAP signal

Background: Recent reports highlighted the possibility that Yes-associated protein (YAP) and transforming growth factor-β1 (TGF-β1) can act as critical regulators of hepatic stellate cells (HSCs) activation; therefore, it is natural for compounds targeting Hippo/YAP and TGF-β1/Smad signaling pathways to be identified as potential anti-fibrotic candidates. Purpose: Liquiritigenin (LQ) is an aglycone of liquiritin and has been reported to protect the liver from injury. However, its effects on the Hippo/YAP and TGF-β1/Smad pathways have not been identified to date. Methods: We conducted a series of experiments using CCl4-induced fibrotic mice and cultured LX-2 cells. Result: LQ significantly inhibited liver fibrosis, as indicated by decreases in regions of hepatic degeneration, inflammatory cell infiltration, and the intensity of α-smooth muscle actin (α-SMA) staining in mice. Moreover, LQ blocked the TGF-β1-induced phosphorylation of Smad 3, and the transcript levels of plasminogen activator inhibitor-1 (PAI-1) and matrix metalloproteinase-2 (MMP-2) in LX-2 cells, which is similar with resveratrol and oxyresveratrol (positive controls). Furthermore, LQ increased activation of large tumor suppressor kinase 1 (LATS1) with the induction of YAP phosphorylation, thereby preventing YAP transcriptional activity and suppressing the expression of exacerbated TGF-β1/Smad signaling molecules. Conclusion: These results clearly show that LQ ameliorated experimental liver fibrosis by acting on the TGF-β1/Smad and Hippo/YAP pathways, indicating that LQ has the potential for effective treatment of liver fibrosis.

-

-

Design, synthesis, and cholinesterase inhibition assay of liquiritigenin derivatives as anti-Alzheimer's activity

The marine environment is a rich resource for discovering functional materials, and seaweed is recognized for its potential use in biology and medicine. Liquiritigenin has been isolated and identified from Sargassum pallidum. To find new anti-Alzheimer's activity, we designed and synthesized thirty-two 7-prenyloxy-2,3-dihydroflavanone derivatives (3a-3p) and 5-hydroxy-7-prenyloxy-2,3-dihydro-flavanone derivatives (4a-4p) as cholinesterases inhibitors based on liquiritigenin as the lead compound. Inhibition screening against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) indicated that all synthesized compounds possessed potent AChE inhibitory activity and moderated to weak BuChE inhibitory activity in vitro. Kinetic studies demonstrated that compound 4o inhibited AChE via a dual binding site ability. In addition, all compounds displayed the radical scavenging effects. Finally, the molecular docking simulation of 4o in AChE active site displayed good agreement with the obtained the pharmacological results.

A method of synthesizing the glycyrrhizin (by machine translation)

The invention relates to a synthetic chemical method of glycyrrhizin. In order to 2, 4 - dihydroxy acetophenone and 4 - hydroxy benzoic acid ethyl ester as the raw material, the protective group for a hydroxyl, keto ester condensation, cyclization and hyd